Treatment for neurologic disorders using stem cells

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study investigates the use of autologous bone marrow-derived stem cells (BMSC) to improve neurologic function in patients with various neurologic disorders. Participants will receive BMSC through intravenous administration and topical application in the nasal passages. The study aims to explore the effectiveness of this treatment approach, particularly in patients with documented functional damage to the nervous system that is unlikely to improve with standard care. The researchers hope to contribute to the existing literature on BMSC treatment for neurologic conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.
2. Be at least 6 months post-onset of the disease.
3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.
4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
5. Be over the age of 18 and capable of providing informed consent.
6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.

Exclusion Criteria:

1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.
2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.
3. Patients must be capable of providing informed consent.
4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .
5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.
6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.

Where it's running

• MD Stem Cells
  Westport, Connecticut, United States Recruiting
• MD Stem Cells
  Coral Springs, Florida, United States Recruiting
• The Saudi-German Hospital
  Dubai, United Arab Emirates, United Arab Emirates Recruiting

Study contacts

• Principal investigator: Jeffrey Weiss, MD — Coral Springs, Florida
• Study coordinator: Steven Levy, MD
• Email: stevenlevy@mdstemcells.com
• Phone: 203-423-9494

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biobank for studying ALS and Alzheimer's diseases

  This study is collecting blood, skin samples, and health information from people to see how genetics might help us understand and find treatments for ALS and Alzheimer's disease.

  Recruiting New York Stem Cell Foundation Research Institute · New York, New York · NCT06203106

• Collecting data on neurodegenerative diseases progression markers

  This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.

  Recruiting IRCCS San Raffaele Roma · Cassino, Frosinone · NCT06596746

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

• Predicting disease progression in dementia using biomarkers and modeling

  This study is trying to create a tool that helps predict how dementia will progress in people with mild cognitive impairment and different types of dementia, like Alzheimer's and Lewy Body Disease, by looking at brain scans, body fluids, and mental tests.

  Recruiting University Health Network, Toronto · North York, Ontario and 3 other locations · NCT06529744

• Cohort study on Alzheimer's risk in first-degree relatives

  This study looks at how likely first-degree relatives of Alzheimer's patients are to develop the disease themselves and what factors might affect that risk.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05597410

• Using a passive home sensor to find digital signs of brain energy changes from nicotinamide riboside

  This project will try a contact-free home sensor to see if it can detect activity, sleep, and breathing changes related to nicotinamide riboside in people with mild cognitive impairment or mild Alzheimer's.

  Recruiting Mclean Hospital · Belmont, Massachusetts · NCT05245903

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.